Valneva SE(VALN)Earnings, Financials & Key Ratios
VALN•NASDAQ
Price updated Jun 19, 2026
AboutValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.Show more
- Revenue$175M+3.0%
- EBITDA-$60M-281.9%
- Net Income-$115M-840.6%
- EPS (Diluted)-1.32-676.5%
- Gross Margin38.66%-7.7%
- EBITDA Margin-34.28%-276.6%
- Operating Margin-46.74%-694.6%
- Net Margin-65.95%-813.2%
- ROE-80.16%-912.8%
VALN Key Insights
Valneva SE (VALN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 12.3% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 19.7% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VALN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VALN Price & Volume
Valneva SE (VALN) stock price & volume — 10-year historical chart
Loading chart...
VALN Growth Metrics
Valneva SE (VALN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.35%
5 Years9.62%
3 Years-21.52%
TTM-15.98%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-71.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-41.74%
Return on Capital
10 Years-13.37%
5 Years-18.17%
3 Years-15.06%
Last Year-23.63%
VALN Recent Earnings
Valneva SE (VALN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.42-100.0%
$0.21
Rev
$36M-33.8%
$55M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.68-293.1%
$0.17
Rev
$56M+6.5%
$52M
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.61-103.3%
$0.30
Rev
$34M-29.5%
$49M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.16+40.7%
$0.27
Rev
$57M+45.5%
$39M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.42vs $0.21-100.0% | $36Mvs $55M-33.8% |
| Q2 2026 | Mar 16, 2026 | $0.68vs $0.17-293.1% | $56Mvs $52M+6.5% |
| Q4 2025 | Nov 20, 2025 | $0.61vs $0.30-103.3% | $34Mvs $49M-29.5% |
| Q3 2025 | Aug 12, 2025 | $0.16vs $0.27+40.7% | $57Mvs $39M+45.5% |
Based on last 12 quarters of dataView full earnings history →
VALN Peer Comparison
Valneva SE (VALN) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 DYAI | 28.5M | 0.78 | -3.40 | -64.74% | -245.12% | -10.05% | 4.11 | |
 IBRX | 7.71B | 7.36 | -19.37 | 6.68% | -6.06% | |||
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 |
Compare VALN vs Peers
Valneva SE (VALN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VALN Income Statement
Valneva SE (VALN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 105.29M | 113.03M | 126.2M | 110.32M | 348.08M | 361.3M | 153.71M | 169.58M | 174.66M | 156.33M |
Revenue Growth % | 11.94% | 7.35% | 11.64% | -12.58% | 215.52% | 3.8% | -57.46% | 10.32% | 3% | -15.98% |
Cost of Goods Sold | 45.98M | 43.43M | 49.97M | 54.3M | 187.92M | 324.44M | 100.88M | 98.54M | 107.14M | 110.28M |
COGS % of Revenue | 43.67% | 38.42% | 39.6% | 49.22% | 53.99% | 89.8% | 65.63% | 58.11% | 61.34% | - |
Gross Profit | 59.31M▲ 0% | 69.6M▲ 17.4% | 76.23M▲ 9.5% | 56.02M▼ 26.5% | 160.16M▲ 185.9% | 36.86M▼ 77.0% | 52.84M▲ 43.3% | 71.04M▲ 34.5% | 67.52M▼ 5.0% | 46.05M▲ 0% |
Gross Margin % | 56.33% | 61.58% | 60.4% | 50.78% | 46.01% | 10.2% | 34.37% | 41.89% | 38.66% | 29.46% |
Gross Profit Growth % | 16.33% | 17.35% | 9.52% | -26.51% | 185.91% | -76.98% | 43.34% | 34.45% | -4.96% | - |
Operating Expenses | 63.27M | 63.34M | 74.23M | 111.13M | 221.56M | 150.31M | 134.92M | 57.71M | 149.15M | 145.42M |
OpEx % of Revenue | 60.09% | 56.03% | 58.82% | 100.73% | 63.65% | 41.6% | 87.78% | 34.03% | 85.4% | - |
Selling, General & Admin | 33.42M | 48.04M | 42.54M | 45.52M | 71.25M | 57.58M | 96.55M | 95.11M | 74.68M | 70.46M |
SG&A % of Revenue | 31.74% | 42.5% | 33.71% | 41.26% | 20.47% | 15.94% | 62.81% | 56.08% | 42.76% | - |
Research & Development | 23.36M | 12.19M | 37.88M | 84.45M | 173.28M | 104.92M | 59.89M | 74.14M | 85.3M | 85.56M |
R&D % of Revenue | 22.18% | 10.79% | 30.02% | 76.55% | 49.78% | 29.04% | 38.97% | 43.72% | 48.84% | - |
Other Operating Expenses | 6.49M | 19.83M | -3.07M | -18.85M | -22.98M | -12.2M | -21.52M | -111.54M | -10.83M | -4M |
Operating Income | -3.95M▲ 0% | 6.26M▲ 258.3% | -811K▼ 113.0% | -55.11M▼ 6695.3% | -61.39M▼ 11.4% | -113.44M▼ 84.8% | -82.09M▲ 27.6% | 13.33M▲ 116.2% | -81.63M▼ 712.4% | -99.37M▲ 0% |
Operating Margin % | -3.76% | 5.54% | -0.64% | -49.95% | -17.64% | -31.4% | -53.4% | 7.86% | -46.74% | -63.56% |
Operating Income Growth % | 90.71% | 258.35% | -112.95% | -6695.31% | -11.4% | -84.79% | 27.64% | 116.24% | -712.39% | - |
EBITDA | 7.19M | 13.09M | 7.72M | -45.31M | -47.11M | -92.41M | -64.5M | 32.92M | -59.88M | -96.6M |
EBITDA Margin % | 6.83% | 11.58% | 6.12% | -41.07% | -13.53% | -25.58% | -41.96% | 19.41% | -34.28% | -61.79% |
EBITDA Growth % | 122.96% | 82.12% | -41.01% | -686.85% | -3.97% | -96.15% | 30.2% | 151.03% | -281.92% | -94.18% |
D&A (Non-Cash Add-back) | 11.14M | 6.83M | 8.53M | 9.8M | 14.28M | 21.04M | 17.58M | 19.59M | 21.75M | 0 |
EBIT | -7.5M | 7.14M | 1.76M | -54.56M | -53.02M | -125.76M | -75.3M | 12.5M | -72.22M | -96.6M |
Net Interest Income | -4.99M | -3.61M | -2.43M | -10.62M | -16.71M | -18.79M | -22.11M | -21.62M | -40.09M | -39.12M |
Interest Income | 72K | 178K | 199K | 119K | 249K | 260K | 1.21M | 2.36M | 1.8M | 1.89M |
Interest Expense | 5.06M | 3.79M | 2.63M | 10.74M | 16.96M | 19.05M | 23.32M | 23.98M | 41.9M | 41.01M |
Other Income/Expense | -8.61M | -2.91M | -59K | -10.18M | -8.59M | -31.37M | -16.54M | -24.82M | -32.49M | -38.24M |
Pretax Income | -12.56M▲ 0% | 3.35M▲ 126.7% | -870K▼ 126.0% | -65.3M▼ 7406.0% | -69.98M▼ 7.2% | -144.81M▼ 106.9% | -98.63M▲ 31.9% | -11.49M▲ 88.4% | -114.12M▼ 893.5% | -137.61M▲ 0% |
Pretax Margin % | -11.93% | 2.96% | -0.69% | -59.19% | -20.1% | -40.08% | -64.16% | -6.77% | -65.34% | -88.03% |
Income Tax | -1.08M | 88K | 874K | -909K | 3.45M | -1.54M | 2.8M | 761K | 1.07M | 423K |
Effective Tax Rate % | 8.58% | 2.63% | -100.46% | 1.39% | -4.92% | 1.06% | -2.84% | -6.63% | -0.94% | -0.31% |
Net Income | -11.48M▲ 0% | 3.26M▲ 128.4% | -1.74M▼ 153.4% | -64.39M▼ 3592.3% | -73.42M▼ 14.0% | -143.28M▼ 95.1% | -101.43M▲ 29.2% | -12.25M▲ 87.9% | -115.19M▼ 840.6% | -138.03M▲ 0% |
Net Margin % | -10.9% | 2.89% | -1.38% | -58.37% | -21.09% | -39.66% | -65.99% | -7.22% | -65.95% | -88.3% |
Net Income Growth % | 76.66% | 128.43% | -153.43% | -3592.26% | -14.03% | -95.14% | 29.21% | 87.93% | -840.57% | -71.71% |
Net Income (Continuing) | -11.48M | 2.14M | -1.74M | -64.39M | -73.42M | -143.28M | -101.43M | -12.25M | -115.19M | -138.03M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.30▲ 0% | 0.08▲ 126.7% | -0.04▼ 147.5% | -1.42▼ 3636.8% | -1.50▼ 5.6% | -2.48▼ 65.3% | -1.46▲ 41.1% | -0.17▲ 88.4% | -1.32▼ 676.5% | -1.60▲ 0% |
EPS Growth % | 77.27% | 126.67% | -147.5% | -3636.84% | -5.63% | -65.33% | 41.13% | 88.36% | -676.47% | -41.74% |
EPS (Basic) | -0.30 | 0.08 | -0.04 | -1.42 | -1.50 | -2.48 | -1.46 | -0.17 | -1.32 | - |
Diluted Shares Outstanding | 38.72M | 40.8M | 45.87M | 45.38M | 48.81M | 57.74M | 69.31M | 70.26M | 84.09M | 86.04M |
Basic Shares Outstanding | 38.27M | 40.26M | 45.87M | 45.38M | 48.81M | 57.74M | 69.47M | 70.26M | 84.09M | 86.04M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VALN Balance Sheet
Valneva SE (VALN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 83.45M | 125.97M | 129.16M | 308.43M | 585.83M | 424.66M | 262.82M | 299.01M | 222.54M | 201.65M |
Cash & Short-Term Investments | 33.55M | 77.08M | 64.44M | 204.39M | 346.64M | 289.43M | 126.08M | 168.27M | 109.65M | 105.37M |
Cash Only | 33.55M | 77.08M | 64.44M | 204.39M | 346.64M | 289.43M | 126.08M | 168.27M | 109.65M | 105.37M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 17.62M | 11.26M | 24.03M | 19.23M | 44.01M | 23.91M | 41.65M | 35.2M | 27.81M | 10.14M |
Days Sales Outstanding | 61.09 | 36.36 | 69.5 | 63.63 | 46.15 | 24.16 | 98.89 | 75.78 | 58.12 | 47.95 |
Inventory | 19.93M | 22.73M | 25.77M | 26.93M | 124.1M | 35.1M | 44.47M | 53.66M | 50.23M | 50.64M |
Days Inventory Outstanding | 158.22 | 191 | 188.26 | 181.03 | 241.04 | 39.49 | 160.89 | 198.78 | 171.13 | 187.74 |
Other Current Assets | 7.84M | 10.26M | 14.92M | 57.83M | 71.04M | 76.21M | 50.63M | 41.87M | 34.85M | 35.49M |
Total Non-Current Assets | 105.89M | 103.93M | 135.56M | 140.74M | 231.52M | 196.69M | 197.24M | 201.02M | 176.3M | 170.75M |
Property, Plant & Equipment | 38.37M | 38M | 69.34M | 78.15M | 173.83M | 154.04M | 156.59M | 158.12M | 138.03M | 133.75M |
Fixed Asset Turnover | 2.74x | 2.97x | 1.82x | 1.41x | 2.00x | 2.35x | 0.98x | 1.07x | 1.27x | 1.11x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 48.47M | 44.89M | 41.81M | 35.41M | 32.7M | 28.71M | 25.57M | 25.26M | 22.35M | 21.65M |
Long-Term Investments | 335K | 1.12M | 2.26M | 2.13M | 2.12M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 17.03M | 17.23M | 17.16M | 19.47M | 19.28M | 8.3M | 8.49M | 8.04M | 7.59M | 7.58M |
Total Assets | 189.34M▲ 0% | 229.91M▲ 21.4% | 264.72M▲ 15.1% | 449.16M▲ 69.7% | 817.35M▲ 82.0% | 621.34M▼ 24.0% | 460.06M▼ 26.0% | 500.03M▲ 8.7% | 398.84M▼ 20.2% | 372.4M▲ 0% |
Asset Turnover | 0.56x | 0.49x | 0.48x | 0.25x | 0.43x | 0.58x | 0.33x | 0.34x | 0.44x | 0.37x |
Asset Growth % | -8.48% | 21.42% | 15.14% | 69.67% | 81.97% | -23.98% | -25.96% | 8.69% | -20.24% | -54.95% |
Total Current Liabilities | 37.67M | 42.95M | 41.3M | 175.87M | 368.98M | 277.39M | 158.86M | 114.58M | 93.33M | 94.32M |
Accounts Payable | 5.26M | 9.18M | 8.87M | 24.9M | 16.04M | 14.51M | 17.56M | 12.64M | 9.07M | 21.83M |
Days Payables Outstanding | 41.74 | 77.11 | 64.78 | 167.36 | 31.14 | 16.32 | 63.55 | 46.82 | 30.91 | 55.19 |
Short-Term Debt | 16.54M | 16.66M | 2M | 6.99M | 7.11M | 11.58M | 44.08M | 20.85M | 17.91M | 18.27M |
Deferred Revenue (Current) | 0 | 1.68M | 694K | 89.58M | 124.02M | 9.41M | 5.7M | 3.01M | 432K | 1.8M |
Other Current Liabilities | 7.48M | 6.03M | 13.22M | 35.53M | 159.37M | 184.01M | 55.88M | 44.59M | 40.8M | 50.99M |
Current Ratio | 2.22x | 2.93x | 3.13x | 1.75x | 1.59x | 1.53x | 1.65x | 2.61x | 2.38x | 2.14x |
Quick Ratio | 1.69x | 2.40x | 2.50x | 1.60x | 1.25x | 1.40x | 1.37x | 2.14x | 1.85x | 1.60x |
Cash Conversion Cycle | 177.57 | 150.25 | 192.98 | 77.31 | 256.04 | 47.33 | 196.23 | 227.73 | 198.34 | 180.5 |
Total Non-Current Liabilities | 59M | 43.78M | 88.27M | 195.87M | 277.79M | 124.15M | 172.95M | 204.2M | 199.33M | 201.1M |
Long-Term Debt | 27.43M | 14.27M | 24.32M | 46.38M | 50.73M | 87.23M | 132.77M | 166.52M | 161.26M | 164.23M |
Capital Lease Obligations | 26.66M | 25.8M | 56.59M | 49.39M | 53.69M | 28.16M | 29.09M | 26.43M | 25.34M | 101.14M |
Deferred Tax Liabilities | 65K | 0 | 0 | 412K | 1.29M | 694K | 3.64M | 4.16M | 4.41M | 16.83M |
Other Non-Current Liabilities | -64K | 655K | 6.63M | 99.63M | 167.35M | 8.07M | 7.46M | 7.08M | 8.32M | 8.17M |
Total Liabilities | 96.67M | 86.72M | 129.57M | 371.74M | 646.77M | 401.55M | 331.81M | 318.78M | 292.67M | 295.31M |
Total Debt | 71.5M | 57.6M | 85.22M | 105.45M | 114.66M | 152.38M | 208.82M | 216.31M | 207.25M | 209.72M |
Net Debt | 37.95M | -19.48M | 20.78M | -98.94M | -231.99M | -137.05M | 82.74M | 48.04M | 97.6M | 104.35M |
Debt / Equity | 0.77x | 0.40x | 0.63x | 1.36x | 0.67x | 0.69x | 1.63x | 1.19x | 1.95x | 2.73x |
Debt / EBITDA | 9.95x | 4.40x | 11.04x | - | - | - | - | 6.57x | - | -2.17x |
Net Debt / EBITDA | 5.28x | -1.49x | 2.69x | - | - | - | - | 1.46x | - | -1.08x |
Interest Coverage | -1.48x | 1.88x | 0.67x | -5.08x | -3.13x | -6.60x | -3.23x | 0.52x | -1.72x | -2.36x |
Total Equity | 92.67M▲ 0% | 143.19M▲ 54.5% | 135.15M▼ 5.6% | 77.42M▼ 42.7% | 170.58M▲ 120.3% | 219.8M▲ 28.9% | 128.25M▼ 41.7% | 181.25M▲ 41.3% | 106.17M▼ 41.4% | 76.78M▲ 0% |
Equity Growth % | -7.38% | 54.51% | -5.61% | -42.72% | 120.33% | 28.85% | -41.65% | 41.33% | -41.43% | -116.3% |
Book Value per Share | 2.39 | 3.51 | 2.95 | 1.71 | 3.49 | 3.81 | 1.85 | 2.58 | 1.26 | 0.89 |
Total Shareholders' Equity | 92.67M | 143.19M | 135.15M | 77.42M | 170.58M | 219.8M | 128.25M | 181.25M | 106.17M | 76.78M |
Common Stock | 11.64M | 13.64M | 13.64M | 13.65M | 15.79M | 20.75M | 20.84M | 24.38M | 26.03M | 26.11M |
Retained Earnings | -171.9M | -168.17M | -169.16M | -233.55M | -306.97M | -450.25M | -551.68M | -563.93M | -679.12M | -711.94M |
Treasury Stock | -1.11M | 0 | 0 | 0 | 0 | -645K | -645K | -645K | -645K | 0 |
Accumulated OCI | -34.27M | 0 | 45.76M | 52.34M | 52.51M | 55.25M | 65.73M | 40.15M | 40.74M | 85.08M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VALN Cash Flow Statement
Valneva SE (VALN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 12.83M | 16.31M | 5.53M | 137.74M | 76.9M | -245.34M | -202.74M | -67.22M | -52.89M | -67.49M |
Operating CF Margin % | 12.18% | 14.43% | 4.38% | 124.85% | 22.09% | -67.91% | -131.9% | -39.64% | -30.28% | - |
Operating CF Growth % | 97.22% | 27.1% | -66.09% | 2391.19% | -44.17% | -419.04% | 17.36% | 66.85% | 21.31% | -470.41% |
Net Income | -11.48M | 3.26M | -1.74M | -64.39M | -73.42M | -143.28M | -101.43M | -12.25M | -115.19M | -138.03M |
Depreciation & Amortization | 11.14M | 6.83M | 8.61M | 9.8M | 14.28M | 21.04M | 17.58M | 19.59M | 21.75M | 6.46M |
Stock-Based Compensation | 811K | 1.89M | 2.55M | 6.33M | 14.51M | -8.66M | 5.11M | 7.97M | 9.53M | 0 |
Deferred Taxes | -1.08M | 88K | 874K | -909K | 3.45M | -1.54M | 2.8M | 761K | 1.07M | 752.25K |
Other Non-Cash Items | 10.38M | 1.25M | -1.76M | 20.7M | 81.96M | 33.07M | 18.25M | -71.72M | 30.09M | 46.24M |
Working Capital Changes | 3.06M | 2.99M | -3M | 166.21M | 36.13M | -145.98M | -145.06M | -11.57M | -148K | 25.29M |
Change in Receivables | 597K | 4.34M | -17.28M | -24.02M | -21.35M | 12.4M | -2.85M | 15.71M | 13.33M | 0 |
Change in Inventory | 1.06M | -2.79M | -2.42M | -4.2M | -92.37M | 84.22M | -9.16M | -6.8M | 1.03M | 0 |
Change in Payables | 2.54M | 0 | 13.01M | 6.54M | 35.24M | -14.05M | -17.4M | 0 | 0 | 0 |
Cash from Investing | -4.06M | -2.92M | -10.69M | -19.34M | -93.12M | -29.05M | -20.59M | 76.92M | -1.71M | -5.77M |
Capital Expenditures | -4.04M | -3.17M | -10.88M | -19.47M | -93.17M | -29.32M | -14.23M | -13.87M | -4.42M | -3.43M |
CapEx % of Revenue | 3.84% | 2.81% | 8.62% | 17.65% | 26.77% | 8.12% | 9.26% | 8.18% | 2.53% | 2.19% |
Acquisitions | 0 | 76K | 0 | 0 | 0 | 8K | -10.95M | 0 | 0 | 57.12K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 72K | 254K | 199K | 131K | 55K | 260K | 4.6M | 90.78M | 1.87M | -3.78M |
Cash from Financing | -10.44M | 30.95M | -7.7M | 21.74M | 154.5M | 215.12M | 63.08M | 30.68M | -621K | 33.89M |
Debt Issued (Net) | -5.31M | -14.15M | -2.61M | 26.16M | -3.9M | 34.49M | 75.89M | -6.49M | 61K | 760.99K |
Equity Issued (Net) | -147K | 49.26M | -2.46M | 290K | 166.82M | 189.84M | -240K | 57.14M | 30M | 11.45M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -147K | -23K | -2.48M | 0 | 0 | 0 | -240K | 0 | 0 | 0 |
Other Financing | -4.98M | -4.17M | -2.62M | -4.71M | -8.42M | -9.21M | -12.57M | -19.97M | -30.68M | 21.69M |
Net Change in Cash | -1.72M▲ 0% | 43.54M▲ 2628.4% | -12.64M▼ 129.0% | 140M▲ 1207.1% | 142.29M▲ 1.6% | -57.21M▼ 140.2% | -160.45M▼ 180.5% | 42.19M▲ 126.3% | -58.62M▼ 238.9% | -53.7M▲ 0% |
Free Cash Flow | 8.79M▲ 0% | 13.13M▲ 49.4% | -5.36M▼ 140.8% | 118.27M▲ 2308.5% | -16.27M▼ 113.8% | -274.67M▼ 1588.2% | -217.06M▲ 21.0% | -83.66M▲ 61.5% | -57.38M▲ 31.4% | -70.92M▲ 0% |
FCF Margin % | 8.35% | 11.62% | -4.24% | 107.2% | -4.67% | -76.02% | -141.21% | -49.34% | -32.85% | -45.36% |
FCF Growth % | 211.41% | 49.41% | -140.77% | 2308.53% | -113.76% | -1588.17% | 20.97% | 61.46% | 31.42% | -4.57% |
FCF per Share | 0.23 | 0.32 | -0.12 | 2.61 | -0.33 | -4.76 | -3.13 | -1.19 | -0.68 | -0.82 |
FCF Conversion (FCF/Net Income) | -1.12x | 5.00x | -3.17x | -2.14x | -1.05x | 1.71x | 2.00x | 5.49x | 0.46x | 0.51x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VALN Key Ratios
Valneva SE (VALN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -11.92% | 2.77% | -1.25% | -60.58% | -59.21% | -73.41% | -58.29% | -7.91% | -80.16% | -106.21% |
Return on Invested Capital (ROIC) | -2.13% | 3.69% | -0.43% | -61.5% | - | -797.32% | -41.92% | 4.54% | -28.27% | -36.81% |
Gross Margin | 56.33% | 61.58% | 60.4% | 50.78% | 46.01% | 10.2% | 34.37% | 41.89% | 38.66% | 29.46% |
Net Margin | -10.9% | 2.89% | -1.38% | -58.37% | -21.09% | -39.66% | -65.99% | -7.22% | -65.95% | -88.3% |
Debt / Equity | 0.77x | 0.40x | 0.63x | 1.36x | 0.67x | 0.69x | 1.63x | 1.19x | 1.95x | 2.73x |
Interest Coverage | -1.48x | 1.88x | 0.67x | -5.08x | -3.13x | -6.60x | -3.23x | 0.52x | -1.72x | -2.36x |
FCF Conversion | -1.12x | 5.00x | -3.17x | -2.14x | -1.05x | 1.71x | 2.00x | 5.49x | 0.46x | 0.51x |
Revenue Growth | 11.94% | 7.35% | 11.64% | -12.58% | 215.52% | 3.8% | -57.46% | 10.32% | 3% | -15.98% |
Related:VALN Dividend History·VALN Revenue History·VALN Price History·VALN P/E History·VALN Financial Ratios·VALN Institutional Holders
VALN Frequently Asked Questions
Valneva SE (VALN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Valneva SE (VALN) reported $156.3M in revenue for fiscal year 2025. This represents a 5092% increase from $3.0M in 2005.
Valneva SE (VALN) grew revenue by 3.0% over the past year. Growth has been modest.
Valneva SE (VALN) reported a net loss of $138.0M for fiscal year 2025.
Dividend & Returns
Valneva SE (VALN) has a return on equity (ROE) of -80.2%. Negative ROE indicates the company is unprofitable.
Valneva SE (VALN) had negative free cash flow of $70.9M in fiscal year 2025, likely due to heavy capital investments.